Photo by freestocks from unsplash
In the current landscape of bladder cancer management, marked survival differences exist between non-muscle invasive, muscle invasive and metastatic disease (5-year survival 95%, 50% and 6%, respectively) (1). The rationale… Click to show full abstract
In the current landscape of bladder cancer management, marked survival differences exist between non-muscle invasive, muscle invasive and metastatic disease (5-year survival 95%, 50% and 6%, respectively) (1). The rationale for a multi-modal approach to muscle-invasive bladder cancer (MIBC) is to maximize curative treatment outcomes and prevent progression to metastatic disease.
Keywords:
era perioperative;
putting guidelines;
guidelines practice;
practice era;
perioperative chemotherapy;
muscle invasive
Journal Title: Translational Andrology and Urology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Translational Andrology and Urology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!